Recent reports implicate poly(ADP-ribose) polymerase-1 (PARP-1) in the activation of nuclear factor kappaB (NF-κB). We investigated the role of PARP-1 in the NF-κB signalling cascade induced by ionizing radiation (IR). AG14361, a potent PARP-1 inhibitor, was used in two breast cancer cell lines expressing different levels of constitutively activated NF-κB, as well as mouse embryonic fibroblasts (MEFs) proficient or deficient for PARP-1 or NF-κB p65. In the breast cancer cell lines, AG14361 had no effect on IR-induced degradation of IκBα or nuclear translocation of p50 or p65. However, AG14361 inhibited IR-induced NF-κB-dependent transcription of a luciferase reporter gene. Similarly, in PARP-1−/− MEFs, IR-induced nuclear translocation of p50 and p65 was normal, but κB binding and transcriptional activation did not occur. AG14361 sensitized both breast cancer cell lines to IR-induced cell killing, inhibited IR-induced XIAP expression and increased caspase-3 activity. However, AG14361 failed to increase IR-induced caspase activity when p65 was knocked down by siRNA. Consistent with this, AG14361 sensitized p65+/+ but not p65−/− MEFs to IR. We conclude that PARP-1 activity is essential in the upstream regulation of IR-induced NF-κB activation. These data indicate that potentiation of IR-induced cytotoxicity by AG14361 is mediated solely by inhibition of NF-κB activation.
Nuclear factor kappaB (NF-κB) represents a family of inducible transcription factors that regulates the expression of genes involved in apoptosis and cell proliferation. NF-κB exists as a heterodimeric complex of Rel family proteins (p50, p52, p65, cRel and RelB) that is physically confined to the cytoplasm through its interaction with inhibitor κB (IκB) proteins. Mammary NF-κB consists predominantly of p65/p50 heterodimers (Cao and Karin, 2003). Upon stimulation by inflammatory cytokines or DNA damage, several signalling cascades converge at the IκB kinase (IKK) complex, which phosphorylates and targets IκBα for degradation, promoting nuclear translocation of NF-κB, where it binds to enhancer/promoter regions of target genes, activating transcription (Ghosh and Karin, 2002).
Aberrant activation of NF-κB is very common in cancers (Rayet and Gelinas, 1999; Bassères and Baldwin, 2006). Elevated NF-κB DNA binding activity has been shown both in breast cancer cell lines and primary breast cancer tissues (Nakshatri et al., 1997; Sovak et al., 1997; Biswas et al., 2004). NF-κB activation has been reported following both low and high doses of ionizing radiation (IR) (Brach et al., 1991; Criswell et al., 2003). DNA damage-activated NF-κB induces antiapoptotic genes, thereby inhibiting apoptosis (Wang et al., 1998; Barkett and Gilmore, 1999). Loss or inhibition of NF-κB activation leads to radiosensitization (Jung and Dritschilo, 2001; Russo et al., 2001; Criswell et al., 2003). Constitutive activation of NF-κB contributes to malignant progression, radio- and chemoresistance and increased metastasis of breast tumours. Thus, inhibition of NF-κB represents a promising therapeutic strategy (Biswas et al., 2001; Wu and Kral, 2005). Although most studies have focussed on the mechanisms and pathways that lead to nuclear localization of NF-κB, nuclear modifications such as phosphorylation and acetylation of NF-κB subunits can affect NF-κB function (Perkins, 2006). Poly(ADP-ribose) polymerase-1 (PARP-1) is now emerging as an essential factor in the nuclear regulation of NF-κB activity.
Poly(ADP-ribose) polymerase-1 plays an important role in modulating the cellular responses to DNA damage (Smith, 2001; Chalmers et al., 2004). We have earlier shown that PARP-1 mediates the repair of both DNA single and double strand breaks induced by IR (Veuger et al., 2003). Recent evidence also supports a role for PARP-1 as a transcriptional co-regulator, with the enzyme being implicated in the control of NF-κB, AP-1, Oct1, and more recently HIF-1α (Kraus and Lis, 2003; Martin-Oliva et al., 2006). The role of PARP-1, more specifically its catalytic activity, in the modulation of NF-κB function is contentious, and is likely to be both cell type- and stimulus-specific (Hassa and Hottiger, 1999; Oliver et al., 1999; Hassa et al., 2005). Furthermore, the role of PARP-1 as a mediator of NF-κB activation in response to IR has not been investigated.
AG14361 is a potent PARP-1 inhibitor (Ki<5 nM) that has earlier been shown to potentiate IR-induced cell killing and enhance tumour regression in xenograft models (Skalitzky et al., 2003; Veuger et al., 2003; Calabrese et al., 2004). We evaluated the impact of AG14361 on constitutive and IR-induced NF-κB activity in breast cancer cell lines, as well as mouse embryonic fibroblasts (MEFs) proficient or deficient for PARP-1 or p65. The data presented here lead us to hypothesize that PARP-1 is an essential mediator of IR-induced NF-κB activation, which in turn is an essential mediator of resistance to IR.
Characterization of cell lines
p65−/− MEFs lacked p65, but showed levels of p50, PARP-1, IκBα and IκBβ similar to that of the p65+/+ cells (Figure 1a). PARP-1−/− MEFs lacked PARP-1 but showed bands of intensity similar to that of the PARP-1+/+ cells for p50, p65, IκBα and IκBβ. The two breast cancer cell lines contained similar levels of PARP-1, p50 and p65. There was very little nuclear p50 or p65 in the PARP-1+/+, PARP-1−/−, p65+/+ and p65−/− MEFs (data not shown). MDA-MB-231 (oestrogen-independent; oestrogen receptor negative, ER−; hereafter referred to as MDA) cells are reported to have higher levels of p50 and p65 in the nucleus and a lower level of IκBβ compared with T47D (oestrogen-dependent; oestrogen receptor positive, ER++) cells (Nakshatri et al., 1997). We also found higher nuclear levels of p50 and p65 in the MDA cells, but no difference in the levels of either IκBα or IκBβ (Figures 1a and b and Supplementary Figure S1). Transient transfection of p65 siRNA resulted in knockdown of p65 protein, and this was maximal (95% reduction) by 48 h (Figure 1c), and persisted up to 72 h. Figure 1d shows that PARP activity was very similar in all the cell lines. We have earlier shown that PARP activity is very low (<5%) in the PARP-1−/− MEFs used here (Veuger et al., 2003).
AG14361 inhibits NF-κB binding to DNA after IR
As predicted from published reports, which used EMSA to measure NF-κB DNA binding activity, the ER− MDA cells contained higher levels of constitutive NF-κB DNA binding activity compared with T47D cells (compare Figures 2a1 and a2) (Nakshatri et al., 1997). IR induced binding of p50 and p65 in both cell lines in a dose-dependent manner 2 h after irradiation (Figure 2a). The binding activity was competed out by a wild-type, but unaffected by a mutant, oligonucleotide (data not shown). Increased binding activity in the MDA cells was detectable after a clinically relevant dose of 1 Gy (Figure 2a1). Similarly, in PARP-1+/+ MEFs, there was a 1.7-fold increase in DNA binding after 1 Gy (Figure 2d). Maximal induction (p50 and p65) occurred at a higher dose of IR in the T47D cell line compared with the MDA cell line (Figure 2a1 versus 2a2—50 Gy compared with 20 Gy). Furthermore, the activation was greater in the T47D cells (15-fold versus 3-fold). Maximal binding occurred by 2 h and returned to basal levels by 8 h (Figures 2b1 and b2). Subsequent experiments used a dose of 20 Gy to ensure maximal NF-κB activation. Importantly, incubation with 0.1 μM AG14361 completely prevented DNA binding 2 h after IR in both cell lines (Figures 2c1 and c2). The DNA binding activity of p50 in the absence of IR in MDA cells was inhibited by >50% by co-incubation with AG14361 for 24 h (Figure 2c3). Nuclear extracts from IR-treated cells were incubated with AG14361 before carrying out the DNA binding assay. No reduction in binding was detected (data not shown) showing that AG14361 does not interfere directly with the interaction of NF-κB with the DNA. Constitutive p50 DNA binding was extremely low in the PARP-1−/− cells compared with the PARP-1+/+ cells (Figure 2d). IR stimulated DNA binding in the PARP-1+/+ (but not the PARP-1−/−) cells, with maximal binding at 10 Gy (Figure 2d).
AG14361 does not affect IκBα degradation or NF-κB nuclear translocation
Ionizing radiation triggered a partial degradation (∼50%) of IκBα (Figure 3a) with maximal degradation occurring by 1 h and returning towards control levels after 4 h. Treatment with AG14361 had no effect on IκBα degradation, but its resynthesis was suppressed (Figure 3a). IR-induced IκBα degradation was also observed in PARP-1−/− MEFs (Figure 3c). In the absence of IR, AG14361 had no effect on IκBα levels when incubated with cells for 72 h (data not shown). Nuclear translocation of both p50 and p65 in the T47D cells was observed 1 h after IR, returning back towards control levels by 2 h, in parallel with the kinetics of IκBα degradation (Figure 3b and Supplementary Figure S1), and this was unaffected by AG14361. Translocation of p50 and p65 occurred in the PARP-1−/− MEFs with similar kinetics to the T47D cell line (Figure 3d and Supplementary Figure S1), in agreement with Oliver et al., 1999.
AG14361 inhibits NF-κB-dependent gene transcription after IR
Induction of luciferase activity 8 h after IR was dose dependent in all cell lines tested (Figure 4). IR did not influence the expression of the internal control plasmid used to monitor transfection efficiency (data not shown). Consistent with the increased DNA binding, the levels of constitutive luciferase expression were higher in the MDA cell line, and maximal luciferase activity occurred at a lower dose compared with the T47D cell line (10 and 50 Gy, respectively) (Figures 4a and b). AG14361 (0.1 μM) inhibited transcriptional activation by at least 80% at all IR doses tested. Figure 4b shows that the constitutive luciferase expression was about 10-fold lower in the PARP-1−/− than the PARP-1+/+ cells, consistent with an earlier report (Carrillo et al., 2004). IR failed to activate gene transcription in the PARP-1−/− cells, but clearly stimulated luciferase expression in the PARP-1+/+ cells.
AG14361 increases apoptosis after IR
Caspase-3 activity is upregulated in cells with reduced NF-κB signalling (Cardoso and Oliveira, 2003). Caspase-3 activity was induced by 20 Gy IR in a time-dependent manner in both breast cancer cell lines (Figure 5a1 and a2), and this was maximal by 24 h. P65 knockdown by siRNA and AG14361 were used to assess their effects on IR-induced caspase-3 activity (Figure 5b1 and b2). Compared with IR alone, both p65 knockdown and AG14361 significantly increased caspase-3 activity to approximately the same extent in both cell lines. Importantly, when AG14361 was used in conjunction with p65 knockdown, there was no significant difference in the caspase-3 activity compared with either agent alone. XIAP (X-linked inhibitor of apoptosis) is the most potent caspase inhibitor of the IAP family and its expression is regulated by NF-κB (Xiao et al., 2001). Western analysis showed that the levels of XIAP in the absence of stimulus were higher in the MDA than the T47D cell line (Figure 5c1 versus c2). After IR, XIAP protein was induced in all cell lines except for the p65−/− cell line (Figure 5c3). This induction was partially suppressed by AG14361 in both breast cancer cell lines.
Radiosensitization by AG14361
We investigated the ability of AG14361 to sensitize the breast cancer cell lines to IR by colony-forming assays. The LD90 (lethal dose producing 90% cell kill) values for IR alone for MDA and T47D cell lines were 3.5 and 5.4, respectively (Figure 6a and b). AG14361 sensitized both cell lines to IR (PF90 (potentiation factor at 90% cell kill)=1.2 for both cell lines). The p65−/− cells were 1.3-fold more sensitive than the p65+/+ cells (Figure 6c versus d). This shows a role for NF-κB in preventing IR-induced cell death, and is consistent with data using TNF-α as the inducer in the same cell lines (Beg and Baltimore, 1996). Co-incubation with AG14361 sensitized the p65+/+ cell line 1.3-fold (PF90). In marked contrast, there was no sensitization to IR by AG14361 in the p65−/− cell line at any of the doses tested. Preliminary data show that, as expected, p65 siRNA sensitized the p65+/+ cell line and not the p65−/− cell line to IR. However, when combined with AG14361, there was no additional sensitization compared with either agent alone consistent with caspase data (Data not shown, Jill Hunter, unpublished results).
Exposure of cells to cytotoxic agents and IR increases NF-κB activity (Brach et al., 1991; Criswell et al., 2003), conferring chemo- and radioresistance by induction of antiapoptotic proteins (Wang et al., 1998; Barkett and Gilmore, 1999). We investigated the role of PARP-1 in the individual steps within the NF-κB signalling cascade induced by IR. We showed high constitutive activity of NF-κB in the MDA cells, which was inhibited by prolonged incubation with AG14361. In contrast, constitutive NF-κB activity was low in the T47D cells. IR activated NF-κB in both cell lines, consistent with the studies of Brach et al., 1991, and AG14361 fully inhibited this activation in both cell lines.
Reports suggest that NF-κB activation can occur with or without IκBα degradation after IR (Raju et al., 1998). We observed IR-induced IκBα degradation in all the cell lines tested. Although AG14361 did not inhibit IR-induced degradation of IκBα, its resynthesis was inhibited, indicating that the liberated NF-κB could not induce transcription of the IκBα gene. IR-induced NF-κB-dependent gene transcription, assessed by a luciferase gene reporter assay, was completely inhibited by AG14361, although nuclear translocation of p50 and p65 was unaffected. Very similar results were obtained when PARP-1+/+ cells were compared with PARP-1−/− cells. However, resynthesis of IκBα was unaffected by the absence of PARP-1. This difference may be because inhibited PARP-1 may produce different physiological effects compared with the absence of PARP-1 protein. Although inhibitory effects on other PARP family proteins cannot be rigorously excluded, the consistency in the data obtained from both the inhibitor studies and the PARP-1−/− cell line suggest that this is not the case.
Poly(ADP-ribose) polymerase-1 may modulate transcription either through local modification of chromatin structure and/or modulation of transcription factor activity via physical interactions with proteins including transcription factors, or direct binding to gene regulating sequences (Althaus et al., 1994; Kraus and Lis, 2003). The importance of PARP-1 enzymatic activity for NF-κB activation is controversial. Some groups have reported that PARP-1 enzyme activity directly influences NF-κB-dependent transcription (Chang and Alvarez-Gonzalez, 2001; Chiarugi and Moskowitz, 2003; Nakajima et al., 2004). For example, Chang and Alvarez-Gonzalez (2001), showed that non-poly(ADP-ribosylated) PARP-1 binds NF-κB p50 and blocks its sequence-specific DNA binding and hence prevents transcriptional activation. In cells treated with H2O2, leading to DNA damage and hence PARP-1 activation, this binding is reversed upon PARP-1 automodification, enabling p50 to bind to the DNA and activate NF-κB-dependent transcription. Furthermore, preincubation with the PARP-1 inhibitor 3-aminobenzamide strongly inhibited NF-κB activation. These data are consistent with our results showing that NF-κB activation in response to IR was completely dependent on PARP-1 catalytic activity. Conversely, Hassa et al. (2001), showed that TNF-α-mediated PARP-1 co-activation of the NF-κB transcription factor was attenuated in PARP-1 null cells, but was unaffected by either PARP-1 inhibition or overexpression of a mutant PARP-1 with no catalytic activity. We have also shown that TNF-α activates NF-κB in the MCF7 breast cancer cell line. Whereas knockdown of PARP-1 protein abrogated NF-κB activation, AG14361 had no effect (Martha Watson, unpublished results), consistent with the data of Hassa et al. (2001), Both TNF-α and IR signalling converge to activate NF-κB by the same canonical pathway, viz. IKK activation, resulting in phosphorylation and proteasome-mediated degradation of IκB, freeing NF-κB to translocate to the nucleus. We show here, that PARP-1 mediates activation of NF-κB independent of the signalling pathways through which it is activated. Thus, the differential requirements of TNF-α and IR-activated NF-κB for PARP-1 (protein only versus catalytic activity, respectively) must occur at the DNA binding and transcription stage. The differences in these observations evidently depend on the tissue or cell type and the type of inducing agent used. One possibility is that PARP-1 is not activated by TNF-α and thus inhibition of PARP-1 should have no impact.
Dysregulation of NF-κB pathways is implicated in malignant progression (Nakshatri et al., 1997; Sovak et al., 1997; Biswas et al., 2004). NF-κB was found to be aberrantly elevated in ER− breast cancers and cell lines and our data support these findings. We showed a higher amount of aberrant p50 nuclear localization and DNA binding when compared with p65 in the ER− MDA cell line. Additionally, the level of p50 was higher than p65 in both cell lines after exposure to IR. Zhou et al. (2005), also showed that DNA binding complexes with p50 were more abundant than p65 in breast tumour samples. Where the predominant NF-κB complex is the p50 homodimer, activation after IR would not necessarily be expected to yield a strong transcriptional response. Nevertheless, increased transcriptional activity was observed in both breast cancer cell lines after IR. Complex formation with the IκB homologue, BCl3, provides a mechanism by which IR may induce p50-associated NF-κB transcriptional activity in breast cancer cells, which do not contain high levels of p65 (Pratt et al., 2003).
Radiosensitization can be achieved at clinically relevant doses of IR by inhibiting NF-κB in many cancer cell types (Wang et al., 1996; Jung and Dritschilo, 2001; Russo et al., 2001; Criswell et al., 2003). We have earlier shown that AG14361 potentiates IR-induced cell killing (Veuger et al., 2003). In this study, we showed that AG14361 potentiated IR cytotoxicity in both ER+ and ER− breast cancer cell lines, and that this effect correlated with enhanced caspase-3 activity. P65−/− cells were more radiosensitive than p65+/+ cells, indicating that NF-κB activity is required for protection against cell killing induced by IR. Significantly, AG14361 sensitized the p65+/+, but not the p65−/−, cells to IR, suggesting that AG14361-mediated cell death is dependent on NF-κB function. This notion was substantiated by knocking down p65 in the breast cancer cell lines using siRNA. Similarly to AG14361, p65 knockdown resulted in enhanced caspase-3 activity compared with IR alone. Strikingly, the combination of AG14361 and p65 siRNA showed no additive effects, confirming that NF-κB and PARP-1 are affecting the same pathway. That the AG14361-mediated radiosensitization is solely due to the inhibition of PARP-1 is supported by our earlier observation that AG14361 potentiated IR-induced cytotoxicity in PARP-1+/+, but not PARP-1−/− cells (Veuger et al., 2003).
XIAP is the best characterized of mammalian IAPs and the most potent and versatile of these regulators of cell death (Holcik et al., 2001). XIAP is upregulated in many human tumour types (Ferreira et al., 2001). Yang et al. (2003), showed that downregulation of XIAP significantly enhanced apoptosis. We show here that AG14361 decreased the upregulation of XIAP protein after IR. XIAP mRNA levels were not investigated, as post-translational modifications of apoptosis effectors, including XIAP, (for example, ubiquitylation, phosphorylation) may influence their stability, subcellular targeting and cell death function (Deveraux et al., 1999; Dan et al., 2004). XIAP has recently been shown to inhibit the apoptotic executioners caspase-3 and caspase-7 (Scott et al., 2005). We showed that AG14361 increased caspase-3 activity concomitant with its effect in decreasing XIAP expression. This apoptotic response is p53-independent as both breast cancer cell lines used here are p53 mutant (Concin et al., 2003). Moreover, NF-κB activation occurred in the PARP-1+/+ cells, which we have earlier shown to have a mutant p53, with no activation in the PARP-1−/− cells, although they have a wild type p53 (Veuger et al., 2003).
Several therapeutic approaches have been used to suppress NF-κB activity, including proteasome and IKK inhibitors (Pande and Ramos, 2005). NF-κB inhibitors reduced metastasis in xenograft models (Andela et al., 2000). Parthenolide, which inhibits IKK activity, increased the sensitivity of breast cancer cell lines to taxol (Patel et al., 2000). An NF-κB decoy oligonucleotide stimulated apoptosis and upregulated caspase-3 activity in osteoclasts (Penolazzi et al., 2003). A PARP-1 inhibitor will usefully target NF-κB at the penultimate DNA binding and transcriptional activation stage. The role of PARP-1 is also likely to involve cross talk between different transcriptional factors activated by IR. For example, p53 is induced after IR, and both NF-κB and p53 share the CREB binding protein and p300 as transcriptional coactivators (Webster and Perkins, 1999). Acetylation of PARP-1 by CREB binding protein and p300 has been shown to be involved in the regulation of the NF-κB transcriptional response (Hassa et al., 2005).
In summary, we have shown that PARP-1 function is essential for IR-induced NF-κB activation. Furthermore, the data support the hypothesis that the radiosensitizing effects of AG14361 are a consequence of its effects on NF-κB activity. This hypothesis merits further investigation as it has important consequences for the design of therapeutic strategies deploying PARP-1 inhibitors, which are currently in clinical trials.
Materials and methods
AG14361 was synthesized by Pfizer GRD, CA, USA. AG14361 and PJ-34 (Axxora, Nottingham, UK) were dissolved in anhydrous DMSO at a stock concentration of 10 mM and stored at −20 °C. AG14361 was added in cell culture such that the final DMSO concentration was kept constant at 0.1% (v/v), and was used at a final concentration of 1 μM in all experiments, unless otherwise stated.
Cell lines and culture
Human breast cancer cell lines, MDA and T47D, were obtained from ATCC (Middlesex, UK). PARP-1+/+ and PARP-1−/− MEFs were a gift from Professor Gilbert de Murcia, École Superieure de Biotechnologie de Strasbourg, France. The p65+/+ and p65−/− MEFs were kindly provided by Professor Ron Hay, University of St Andrews, UK. All cell lines were cultured in Dulbecco's modified Eagle's medium (supplemented with 10% (v/v) fetal calf serum, 100 units/ml penicillin, 100 μg/ml streptomycin and 2 mM glutamine).
Cells were seeded, in six-well cell culture plates at a density of 5 × 104 (MDA), or 1 × 105 (T47D) in 2 ml of tissue culture medium and left overnight to adhere. SiRNA targeting human p65 (IndexTermGCCCUAUCCCUUUACGUCA; Dharmacon, Cramlington, UK) was transfected at a final concentration of 50 nM using Lipofectamine 2000 (Invitrogen Ltd, Paisley, UK), according to the manufacturer's instructions. Controls used included non-specific (NS) siRNA and mock/vehicle only transfected cells. P65 knockdown was confirmed by western analysis.
Proteins were resolved on 4–20% (v/v) Tris glycine gradient gels (Invitrogen) and electrotransferred onto nitrocellulose (Bio-Rad, Herts, UK). Antibodies against PARP-1 (H-250), p50 (8414), p65 (8008), IκBα (371), IκBβ (945) and pIκBα (8404) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-XIAP was acquired from R&D systems (Oxfordshire, UK). As loading controls, anti-actin antibody (mouse clone AC-40; Sigma, Dorset, UK) was used for whole cell extracts, anti-lamin A/C (7293; Santa Cruz Biotechnology) for nuclear extracts and α-tubulin for cytoplasmic extracts (8035; Santa Cruz Biotechnology). This was followed by binding of peroxidase-conjugated goat anti-mouse/rabbit antibody (DAKO, Ely, UK) and detection by enhanced chemiluminescence (Amersham International, Buckinghamshire, UK). Cells were pretreated with AG14361 for 60 min and exposed to IR. Cells were harvested at different time points and whole cell extracts were taken using SDS lysis buffer (100 mM Tris Hcl pH 6.8, 20% v/v glycerol, 4% w/v SDS). Nuclear and cytoplasmic extracts were prepared using the NE-PER extraction kit as per manufacturer's instructions (Pierce-Perbio science, Cheshire, UK). No α-tubulin was detected in nuclear extracts and conversely, lamin was absent in all cytoplasmic extracts, thus showing the efficiency of the kit (Supplementary Figure S1). Bands were quantified and normalized to their relevant loading controls using densitometry (Bio-Rad Gel Doc, Quantity One, Herts, UK).
NF-κB DNA binding assay
p50 and p65 DNA binding activities were determined using an ELISA-based EZ-detect assay according to the manufacturer's instructions (Promega, Southampton, UK). Briefly, streptavidin-coated 96-well plates are bound with biotinylated κB consensus sequence oligonucleotides (5′-IndexTermGGGACTTTCC-3′). Nuclear extracts (prepared as above) were added to each well and incubated with primary antibody specific for either p50 or p65. Binding was detected using a secondary HRP-conjugated antibody and chemiluminescence was measured using a CCD camera (LAS-300; Fujifilm). We have probed for PARP-1, histones and lamin in nuclear and cytoplasmic fractions, and these proteins were only detected in the nuclear fractions (data not shown). Results were normalized to chemiluminescence per μg protein using the BCA protein assay as per manufacturer's instructions (Pierce-Perbio science).
Reporter gene assay
Cells were seeded onto 96-well plates and incubated for 24 h. Cells were transiently transfected with 200 ng of an NF-κB-luciferase construct containing three tandemly repeated NF-κB consensus sequence binding sites in the promoter (Professor Ron Hay, St Andrews University), together with 200 ng of a pCMB-β-galactosidase plasmid containing a minimal promoter element upstream from the β-galactosidase gene, using FuGENE6 transfection reagent (Roche diagnostics, Sussex, UK) for 6 h. Twenty-four hours after transfection, cells were treated with AG14361 for 1 h before IR. After an 8-h incubation, cells were lysed and assayed for luciferase activity according to the manufacturer's instructions (Promega). Luciferase activity was corrected for β-galactosidase activity as described earlier, and relative activities were expressed as fold changes.
Caspase-3 activity was determined using the Caspase-Glo 3/7 kit (Promega). Cells were seeded onto a 96-well plate and incubated for 24 h. Cells were transfected with 50 nM siRNA, 50 nM NS siRNA or Lipofectamine 2000 (Invitrogen) and incubated for 48 h. Cells were treated with AG14361 for 60 min before IR and allowed to recover at 37 °C before addition of Caspase-Glo 3/7 reagent to the culture medium at a 1:1 ratio, shaken for 30 s and incubated at room temperature for 2 h. Cell lysates were transferred to a white-walled 96-well plate. Luminescence was measured using a microplate luminometer (Perkin Elmer, Buckinghamshire, UK). Data were normalized to untreated controls.
PARP activity assay
PARP activity was assayed by measuring incorporation of radiolabel from [32P] NAD+ into acid precipitable counts in a permeabilized cell system (Grube et al., 1991). A 30-bp blunt-ended oligonucleotide was used to maximally activate PARP.
Clonogenic assays were carried out as described earlier (Veuger et al., 2003). Data were normalized to untreated controls. PF90 values were calculated from the ratio of the individual LD90 values: that is, LD90 divided by LD90 in the presence of AG14361.
Althaus FR, Hofferer L, Kleczkowska HE, Malanga M, Naegeli H, Panzeter PL et al. (1994). Histone shuttling by poly ADP-ribosylation. Mol Cell Biochem 138: 53–59.
Andela VB, Schwarz EM, Puzas JE, O’Keefe RJ, Rosier RN . (2000). Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Res 60: 6557–6562.
Barkett M, Gilmore TD . (1999). Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18: 6910–6924.
Bassères DS, Baldwin AS . (2006). Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817–6830.
Beg AA, Baltimore D . (1996). An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274: 782–784.
Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, Pardee AB . (2001). The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci USA 98: 10386–10391.
Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB et al. (2004). NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101: 10137–10142.
Brach M, Hass R, Sherman M, Gunji H, Weichselbaum R, Kufe D . (1991). Ionizing radiation induces expression and binding activity of the nuclear factor kB. J Clin Invest 88: 691–695.
Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S et al. (2004). Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96: 56–67.
Cao Y, Karin M . (2003). NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 8: 215–223.
Cardoso SM, Oliveira CR . (2003). Inhibition of NF-kB renders cells more vulnerable to apoptosis induced by amyloid beta peptides. Free Radic Res 37: 967–973.
Carrillo A, Monreal Y, Ramirez P, Marin L, Parrilla P, Oliver FJ et al. (2004). Transcription regulation of TNF-alpha-early response genes by poly(ADP-ribose) polymerase-1 in murine heart endothelial cells. Nucleic Acids Res 32: 757–766.
Chalmers A, Johnston P, Woodcock M, Joiner M, Marples B . (2004). PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys 58: 410–419.
Chang WJ, Alvarez-Gonzalez R . (2001). The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1. J Biol Chem 276: 47664–47670.
Chiarugi A, Moskowitz MA . (2003). Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem 85: 306–317.
Concin N, Zeillinger C, Tong D, Stimpfl M, Konig M, Printz D et al. (2003). Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. Breast Cancer Res Treat 79: 37–46.
Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA . (2003). Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 22: 5813–5827.
Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG et al. (2004). Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279: 5405–5412.
Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Read GC . (1999). Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 18: 5242–5251.
Ferreira C, van der Valk P, Span S, Jonker J, Postmus P, Kruyt F et al. (2001). Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann Oncol 12: 799–805.
Ghosh S, Karin M . (2002). Missing pieces in the NF-kappaB puzzle. Cell 109 (Suppl): S81–S96.
Grube K, Kupper JH, Burkle A . (1991). Direct stimulation of poly(ADP ribose) polymerase in permeabilized cells by double-stranded DNA oligomers. Anal Biochem 193: 236–239.
Hassa PO, Covic M, Hasan S, Imhof R, Hottiger MO . (2001). The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function. J Biol Chem 276: 45588–45597.
Hassa PO, Haenni SS, Buerki C, Meier NI, Lane WS, Owen H et al. (2005). Acetylation of PARP-1 by p300/CBP regulates coactivation of NF-kappa B-dependent transcription. J Biol Chem 280: 40450–40464.
Hassa PO, Hottiger MO . (1999). A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. J Biol Chem 380: 953–959.
Holcik N, Gibson H, Korneluk RG . (2001). XIAP: apoptotic brake and promising therapeutic target. Apoptosis 6: 253.
Jung M, Dritschilo A . (2001). NF-kappa B signaling pathway as a target for human tumor radiosensitization. Semin Radiat Oncol 11: 346–351.
Kraus W, Lis J . (2003). PARP goes transcription. Cell 113: 677–683.
Martin-Oliva D, Aguilar-Quesada R, O’valle F, Munoz-Gamez JA, Martinez-Romero R, Garcia Del Moral R et al. (2006). Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res 66: 5744–5756.
Nakajima H, Nagaso H, Kakui N, Ishikawa M, Hiranuma T, Hoshiko S . (2004). Critical role of the automodification of poly(ADP-ribose) polymerase-1 in nuclear factor-kappaB-dependent gene expression in primary cultured mouse glial cells. J Biol Chem 279: 42774–42786.
Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW . (1997). Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629–3639.
Oliver FJ, Menissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S et al. (1999). Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 18: 4446–4454.
Pande V, Ramos MJ . (2005). NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. Curr Med Chem 12: 357–374.
Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S et al. (2000). Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19: 4159–4169.
Penolazzi L, Lambertini E, Borgatti M . (2003). Decoy oligodeoxynucleotides targeting NFkB transcription factors: induction of apoptosis in human primary osteoclasts. Biochem Pharmacol 66: 1189–1198.
Perkins ND . (2006). Good cop, bad cop: the different faces of NF-kappaB. Oncogene 25: 6717–6730.
Pratt MA, Bishop TE, White D, Yasvinski G, Menard M, Niu MY et al. (2003). Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol 23: 6887–6900.
Raju U, Gumin GJ, Noel F, Tofilon PJ . (1998). IkappaBalpha degradation is not a requirement for the X-ray-induced activation of nuclear factor kappaB in normal rat astrocytes and human brain tumour cells. Int J Radiat Biol 74: 617–624.
Rayet B, Gelinas C . (1999). Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18: 6938–6947.
Russo SM, Tepper JE, Baldwin Jr AS, Liu R, Adams J, Elliott P et al. (2001). Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50: 183–193.
Scott FL, Denault JB, Riedl SJ, Shin H, Renatus M, Salvesen GS . (2005). XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J 24: 645–655.
Skalitzky DJ, Marakovits JT, Maegley KA, Ekker A, Yu XH, Hostomsky Z et al. (2003). Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem 46: 210–213.
Smith S . (2001). The world according to PARP. Trends Biochem Sci 26: 174–179.
Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM et al. (1997). Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952–2960.
Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW . (2003). Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 63: 6008–6015.
Wang CY, Mayo MW, Baldwin Jr AS . (1996). TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784–787.
Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS . (1998). NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680–1683.
Webster GA, Perkins ND . (1999). Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 19: 3485–3495.
Wu JT, Kral JG . (2005). The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 123: 158–169.
Xiao CW, Ash K, Tsang BK . (2001). Nuclear factor-kappaB-mediated X-linked inhibitor of apoptosis protein expression prevents rat granulosa cells from tumor necrosis factor alpha-induced apoptosis. Endocrinology 142: 557–563.
Yang L, Cao Z, Yan H, Wood W . (2003). Coexistence of high levels of apoptotic signalling and inhibitor of apoptosis proteins in human tumour cells: Implications for cancer specific therapy. Cancer Research 63: 6815–6824.
Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U et al. (2005). Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 37: 1130–1144.
This work was supported by the Breast Cancer Campaign, UK and Cancer Research UK.
About this article
Cite this article
Veuger, S., Hunter, J. & Durkacz, B. Ionizing radiation-induced NF-κB activation requires PARP-1 function to confer radioresistance. Oncogene 28, 832–842 (2009). https://doi.org/10.1038/onc.2008.439
- ionizing radiation
Werner syndrome (WRN) DNA helicase and base excision repair (BER) factors maintain endothelial homeostasis
DNA Repair (2019)
Combined Effect of Moringa oleifera and Ionizing Radiation on Survival and Metastatic Activity of Pancreatic Cancer Cells
Integrative Cancer Therapies (2019)
JCI Insight (2019)
Discovery of the Oncogenic Parp1, a Target of bcr-abl and a Potential Therapeutic, in mir-181a/PPFIA1 Signaling Pathway
Molecular Therapy - Nucleic Acids (2019)
Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer
BMC Cancer (2019)